Zobrazeno 1 - 10
of 34
pro vyhledávání: '"José Luis Bello López"'
Autor:
Adrián Mosquera Orgueira, Jose Ángel Díaz Arías, Rocio Serrano Martín, Victor Portela Piñeiro, Miguel Cid López, Andrés Peleteiro Raíndo, Laura Bao Pérez, Marta Sonia González Pérez, Manuel Mateo Pérez Encinas, Máximo Francisco Fraga Rodríguez, Juan Carlos Vallejo Llamas, José Luis Bello López
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Diffuse Large B-cell Lymphoma (DLBCL) is the most common type of aggressive lymphoma. Approximately 60% of fit patients achieve curation with immunochemotherapy, but the remaining patients relapse or have refractory disease, which predicts a short su
Externí odkaz:
https://doaj.org/article/617f5691a8e74047b11c6b9eeaa33179
Autor:
Adrián Mosquera Orgueira, Jose Ángel Díaz Arías, Miguel Cid López, Andrés Peleteiro Raíndo, Alberto López García, Rosanna Abal García, Marta Sonia González Pérez, Beatriz Antelo Rodríguez, Carlos Aliste Santos, Manuel Mateo Pérez Encinas, Máximo Francisco Fraga Rodríguez, José Luis Bello López
Publikováno v:
HemaSphere, Vol 6, Iss 4, p e706 (2022)
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. Despite notable therapeutic advances in the last decades, 30%–40% of affected patients develop relapsed or refractory disease that frequently precludes an infamo
Externí odkaz:
https://doaj.org/article/4028d800fdc4470ea9215a7e8ef0f9b9
Autor:
Adrián Mosquera Orgueira, José Ángel Díaz Arias, Miguel Cid López, Andrés Peleteiro Raíndo, Beatriz Antelo Rodríguez, Carlos Aliste Santos, Natalia Alonso Vence, Ángeles Bendaña López, Aitor Abuín Blanco, Laura Bao Pérez, Marta Sonia González Pérez, Manuel Mateo Pérez Encinas, Máximo Francisco Fraga Rodríguez, José Luis Bello López
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background Thirty to forty percent of patients with Diffuse Large B-cell Lymphoma (DLBCL) have an adverse clinical evolution. The increased understanding of DLBCL biology has shed light on the clinical evolution of this pathology, leading to
Externí odkaz:
https://doaj.org/article/47def9812b5e4561b9a2ffba19e04710
Autor:
Adrián Mosquera Orgueira, Andrés Peleteiro Raíndo, Miguel Cid López, Beatriz Antelo Rodríguez, José Ángel Díaz Arias, Roi Ferreiro Ferro, Natalia Alonso Vence, Ángeles Bendaña López, Aitor Abuín Blanco, Laura Bao Pérez, Paula Melero Valentín, Marta Sonia González Pérez, Claudio Cerchione, Giovanni Martinelli, Pau Montesinos Fernández, Manuel Mateo Pérez Encinas, José Luis Bello López
Publikováno v:
PLoS ONE, Vol 17, Iss 9 (2022)
Externí odkaz:
https://doaj.org/article/7621093bf9e0435ab51db257b2df8022
Autor:
Adrián Mosquera Orgueira, Miguel Cid López, Andrés Peleteiro Raíndo, Aitor Abuín Blanco, Jose Ángel Díaz Arias, Marta Sonia González Pérez, Beatriz Antelo Rodríguez, Laura Bao Pérez, Roi Ferreiro Ferro, Carlos Aliste Santos, Manuel Mateo Pérez Encinas, Máximo Francisco Fraga Rodríguez, Claudio Cerchione, Pablo Mozas, José Luis Bello López
Publikováno v:
Frontiers in Oncology, Vol 11 (2022)
Follicular Lymphoma (FL) has a 10-year mortality rate of 20%, and this is mostly related to lymphoma progression and transformation to higher grades. In the era of personalized medicine it has become increasingly important to provide patients with an
Externí odkaz:
https://doaj.org/article/946e64e6f3364a31836120ae590b10a7
Autor:
Adrián Mosquera Orgueira, Beatriz Antelo Rodríguez, Natalia Alonso Vence, José Ángel Díaz Arias, Nicolás Díaz Varela, Manuel Mateo Pérez Encinas, Catarina Allegue Toscano, Elena María Goiricelaya Seco, Ángel Carracedo Álvarez, José Luis Bello López
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-11 (2019)
Abstract Background Chronic Lymphocytic Leukemia (CLL) is the most frequent lymphoproliferative disorder in western countries and is characterized by a remarkable clinical heterogeneity. During the last decade, multiple genomic studies have identifie
Externí odkaz:
https://doaj.org/article/60df5c8d5999426b86a2243b980611fb
Autor:
Adrián Mosquera Orgueira, Andrés Peleteiro Raíndo, Miguel Cid López, José Ángel Díaz Arias, Marta Sonia González Pérez, Beatriz Antelo Rodríguez, Natalia Alonso Vence, Laura Bao Pérez, Roi Ferreiro Ferro, Manuel Albors Ferreiro, Aitor Abuín Blanco, Emilia Fontanes Trabazo, Claudio Cerchione, Giovanni Martinnelli, Pau Montesinos Fernández, Manuel Mateo Pérez Encinas, José Luis Bello López
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Acute Myeloid Leukemia (AML) is a heterogeneous neoplasm characterized by cytogenetic and molecular alterations that drive patient prognosis. Currently established risk stratification guidelines show a moderate predictive accuracy, and newer tools th
Externí odkaz:
https://doaj.org/article/0c2126a43e2b4b08bd36aea5a3a142eb
Autor:
Adrián Mosquera Orgueira, Roi Ferreiro Ferro, José Ángel Díaz Arias, Carlos Aliste Santos, Beatriz Antelo Rodríguez, Laura Bao Pérez, Natalia Alonso Vence, Ággeles Bendaña López, Aitor Abuin Blanco, Paula Melero Valentín, And Res Peleteiro Raindo, Miguel Cid López, Manuel Mateo Pérez Encinas, Marta Sonia González Pérez, Máximo Francisco Fraga Rodríguez, José Luis Bello López
Publikováno v:
PLoS ONE, Vol 16, Iss 5, p e0248886 (2021)
B-cell lymphoproliferative disorders exhibit a diverse spectrum of diagnostic entities with heterogeneous behaviour. Multiple efforts have focused on the determination of the genomic drivers of B-cell lymphoma subtypes. In the meantime, the aggregati
Externí odkaz:
https://doaj.org/article/754ac779e90d4b05b34d220930ad3e5d
Autor:
Adrián Mosquera Orgueira, Andrés Peleteiro Raíndo, Miguel Cid López, Beatriz Antelo Rodríguez, José Ángel Díaz Arias, Roi Ferreiro Ferro, Natalia Alonso Vence, Ángeles Bendaña López, Aitor Abuín Blanco, Laura Bao Pérez, Paula Melero Valentín, Marta Sonia González Pérez, Claudio Cerchione, Giovanni Martinelli, Pau Montesinos Fernández, Manuel Mateo Pérez Encinas, José Luis Bello López
Publikováno v:
PLoS ONE, Vol 16, Iss 2, p e0247093 (2021)
BackgroundFLT3 mutation is present in 25-30% of all acute myeloid leukemias (AML), and it is associated with adverse outcome. FLT3 inhibitors have shown improved survival results in AML both as upfront treatment and in relapsed/refractory disease. Cu
Externí odkaz:
https://doaj.org/article/cbe01aa7d0234032abc58f5a46490841
Autor:
Adrián Mosquera Orgueira, Beatriz Antelo Rodríguez, José Ángel Díaz Arias, Marta Sonia González Pérez, José Luis Bello López
Publikováno v:
Frontiers in Genetics, Vol 10 (2019)
Chronic lymphocytic leukemia (CLL) is the most frequent lymphoproliferative syndrome in Western countries, and it is characterized by recurrent large genomic rearrangements. During the last decades, array techniques have expanded our knowledge about
Externí odkaz:
https://doaj.org/article/d5cd657121534812a7725e00982db74a